145 related articles for article (PubMed ID: 37855330)
1. Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms.
Cella CA; Cazzoli R; Fazio N; De Petro G; Gaudenzi G; Carra S; Romanenghi M; Spada F; Grossi I; Pallavicini I; Minucci S; Vitale G
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37855330
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Carra S; Gaudenzi G; Dicitore A; Saronni D; Cantone MC; Plebani A; Ghilardi A; Borghi MO; Hofland LJ; Persani L; Vitale G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809722
[TBL] [Abstract][Full Text] [Related]
3. Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.
Spampatti M; Vlotides G; Spöttl G; Maurer J; Göke B; Auernhammer CJ
World J Gastroenterol; 2014 Aug; 20(29):10038-49. PubMed ID: 25110431
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition.
Reuther C; Heinzle V; Spampatti M; Vlotides G; de Toni E; Spöttl G; Maurer J; Nölting S; Göke B; Auernhammer CJ
Neuroendocrinology; 2016; 103(3-4):383-401. PubMed ID: 26338447
[TBL] [Abstract][Full Text] [Related]
5. Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines.
Drozdov I; Kidd M; Gustafsson BI; Svejda B; Joseph R; Pfragner R; Modlin IM
Cancer; 2009 Nov; 115(21):4934-45. PubMed ID: 19634160
[TBL] [Abstract][Full Text] [Related]
6. Modeling Lung Carcinoids with Zebrafish Tumor Xenograft.
Carra S; Gaudenzi G; Dicitore A; Cantone MC; Plebani A; Saronni D; Zappavigna S; Caraglia M; Candeo A; Bassi A; Persani L; Vitale G
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897702
[TBL] [Abstract][Full Text] [Related]
7. The cytotoxic effect of emetine and CGP-74514A studied with the hollow fiber model and ArrayScan assay in neuroendocrine tumors in vitro.
Larsson DE; Hassan SB; Oberg K; Granberg D
Anticancer Agents Med Chem; 2012 Sep; 12(7):783-90. PubMed ID: 22263790
[TBL] [Abstract][Full Text] [Related]
8. Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study.
Dicitore A; Gaudenzi G; Carra S; Cantone MC; Oldani M; Saronni D; Borghi MO; Grotteschi J; Persani L; Vitale G
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001635
[TBL] [Abstract][Full Text] [Related]
9. Zebrafish as an innovative model for neuroendocrine tumors.
Vitale G; Gaudenzi G; Dicitore A; Cotelli F; Ferone D; Persani L
Endocr Relat Cancer; 2014 Feb; 21(1):R67-83. PubMed ID: 24292602
[TBL] [Abstract][Full Text] [Related]
10. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
[TBL] [Abstract][Full Text] [Related]
11. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
Valentino JD; Li J; Zaytseva YY; Mustain WC; Elliott VA; Kim JT; Harris JW; Campbell K; Weiss H; Wang C; Song J; Anthony L; Townsend CM; Evers BM
Clin Cancer Res; 2014 Mar; 20(5):1212-22. PubMed ID: 24443523
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells.
Aburjania Z; Whitt JD; Jang S; Nadkarni DH; Chen H; Rose JB; Velu SE; Jaskula-Sztul R
Molecules; 2020 Oct; 25(21):. PubMed ID: 33114525
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro.
Sacewicz M; Lawnicka H; Siejka A; Stepień T; Krupiński R; Komorowski J; Stepień H
Cancer Lett; 2008 Sep; 268(1):120-8. PubMed ID: 18486324
[TBL] [Abstract][Full Text] [Related]
14. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
15. Fishing for neuroendocrine tumors.
Gaudenzi G; Carra S; Dicitore A; Cantone MC; Persani L; Vitale G
Endocr Relat Cancer; 2020 Jun; 27(6):R163-R176. PubMed ID: 32252025
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
[TBL] [Abstract][Full Text] [Related]
17. Multiple modes of cell death in neuroendocrine tumors induced by artesunate.
Yan G; Dawood M; Böckers M; Klauck SM; Fottner C; Weber MM; Efferth T
Phytomedicine; 2020 Dec; 79():153332. PubMed ID: 32957040
[TBL] [Abstract][Full Text] [Related]
18. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ
Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
